MicroRNA expression in colorectal cancer

Yao

Gastroenterology Research and Practice

et al. 2013

MicroRNA-429 (miR-429) may modify the development and progression of cancers; however, the role of this microRNA in the hepatocellular carcinoma (HCC) has not been well elaborated. Here, we tested miR-429 expression in 138 pathology-diagnosed HCC cases and SMMC-7721 cells. We found that miR-429 was upregulated in HCC tumor tissues and that the high expression of miR-429 was significantly correlated with larger tumor size (odd ratio (OR), 2.70; 95% confidence interval (CI), 1.28–5.56) and higher aflatoxin B1-DNA adducts (OR = 3.13, 95% CI = 1.47–6.67). Furthermore, this microRNA overexpression modified the recurrence-free survival and overall survival of HCC patients. Functionally, miR-429 overexpression progressed tumor cells proliferation and inhibited cell apoptosis. These results indicate for the first time that miR-429 may modify HCC prognosis and tumorigenesis and may be a potential tumor therapeutic target.

Section: Discussionmentioning

confidence: 99%

MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis

Yao

Gastroenterology Research and Practice

et al. 2013

“…Nevertheless, the discovery of microRNAs is a noteworthy progress in medical fields [12]. Recently, their expression has been shown to be specific to tissue and cancer types where they act as tumor suppressors or oncogenes [13]. Clearly, identifying cancer-related genes and understanding their contribution to tumorigenesis are critical steps in controlling cancer [14].…”

Section: Introductionmentioning

confidence: 98%

Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer

Fateh

Feizi

Safaralizadeh

et al. 2016

J Gastrointest Canc

“…Discoveries of effective biomarkers that can guide therapeutic decisions are ambitiously sought in the hopes of achieving the best possible outcomes, minimizing not necessary and toxic procedures. A host of studies have been conducted toward this end [2], [16], [17]. The ideal biomarker to drive clinical treatments should be significant in multivariate analysis while having robust predictive accuracy with few false positive and false negative results.…”

Section: Discussionmentioning

confidence: 99%

Integrated Multidimensional Analysis Is Required for Accurate Prognostic Biomarkers in Colorectal Cancer

Mariani

He²,

McHugh³

et al. 2014

PLoS ONE

CRC cancer is one of the deadliest diseases in Western countries. In order to develop prognostic biomarkers for CRC (colorectal cancer) aggressiveness, we analyzed retrospectively 267 CRC patients via a novel, multidimensional biomarker platform. Using nanofluidic technology for qPCR analysis and quantitative fluorescent immunohistochemistry for protein analysis, we assessed 33 microRNAs, 124 mRNAs and 9 protein antigens. Analysis was conducted in each single dimension (microRNA, gene or protein) using both the multivariate Cox model and Kaplan-Meier method. Thereafter, we simplified the censored survival data into binary response data (aggressive vs. non aggressive cancer). Subsequently, we integrated the data into a diagnostic score using sliced inverse regression for sufficient dimension reduction. Accuracy was assessed using area under the receiver operating characteristic curve (AUC). Single dimension analysis led to the discovery of individual factors that were significant predictors of outcome. These included seven specific microRNAs, four genes, and one protein. When these factors were quantified individually as predictors of aggressive disease, the highest demonstrable area under the curve (AUC) was 0.68. By contrast, when all results from single dimensions were combined into integrated biomarkers, AUCs were dramatically increased with values approaching and even exceeding 0.9. Single dimension analysis generates statistically significant predictors, but their predictive strengths are suboptimal for clinical utility. A novel, multidimensional integrated approach overcomes these deficiencies. Newly derived integrated biomarkers have the potential to meaningfully guide the selection of therapeutic strategies for individual patients while elucidating molecular mechanisms driving disease progression.